Mavenclad - direct healthcare professional communication (DHPC)

Cladribine

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Mavenclad (cladribine) – risk of serious liver injury and new recommendations about liver function monitoring

Key facts

• Medicine name:
  Mavenclad
• Active substance:
  Cladribine
• Therapeutic area (MeSH):
  Multiple Sclerosis
• Regulatory outcome:
  Variation
• DHPC type:
  Adverse event
• Human ATC codes:
  L04AA40
• Dissemination date:
  14/02/2022